"Expediting Access to a Promising New ALS Drug…"
Welcome to Connecting ALS. This week we dig into the latest development out of Amylyx Pharmaceuticals, which recently announced findings of a phase 2 clinical trial of AMX0035, a drug compound shown to be safe and clinically effective at slowing down disease progression.
Join The ALS Association and Northeast ALS Consortium (NEALS) on Friday at 3p ET for an informative webinar. Register here: https://bit.ly/3gVlpG5
This episode was produced by Garrett Tiedemann and is brought to you by The ALS Association’s national office and the Association’s Minnesota/North Dakota/South Dakota Chapter.